



**Michele Cavo**

**Contact**

Michele Cavo

## Publications (15)

Dimopoulos M, Richardson P, Bahlis N, Grosicki S, Cavo M, Beksac M, Legieć W, Liberati A, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach J, Petrucci M, Reece D, White D, Mateos M, Špička I, Lazaroiu M, Berdeja J, Kaufman J, Jou Y, Ganetsky A, Popa McKiver M, Lonial S, Weisel K, Driessen C. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. *Lancet Haematol* 2022; 9:e403–e414.

Ludwig H, Weisel K, Jackson G, Garderet L, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Schreder M, Abildgaard N, Hájek R, Zojer N, Kastritis E, Broijl A, Schjesvold F, Boccadoro M, Caers J, Delforge M, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, Mateos M, Moreau P, Cavo M, Pawlyn C, Zweegman S, Engelhardt M, Driessen C, Cook G, Dimopoulos M, Gay F, Einsele H, Terpos E. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. *Lancet Haematol* 2021; 8:e934–e946.

Sonneveld P, Driessen C, Pour L, Levin M, Bos G, Ypma P, Wu K, van de Velden V, Oliva S, Broijl A, Croockewit A, Boccadoro M, Spencer A, Palumbo G, Offidani M, van de Donk N, Hveding C, Waage A, Minnema M, Troia R, Cornelisse P, Zamagni E, Zander T, Zweegman S, Ludwig H, Aquino S, van der Holt B, Beksac M, Dimopoulos M, Wester R, Hájek R, Gulbrandsen N, Gregersen H, Morelli A, De Rosa L, Cafro A, Gay F, Dozza L, Pantani L, Cavo M. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. *J Clin Oncol* 2021; 39:3613–3622.

Richardson P, Goldschmidt H, Harousseau J, Dytfeld D, Mellqvist U, Chng W, Hou J, Bergsagel P, Riva E, Leleu X, Bladé J, Driessen C, Quach H, Ocio E, Vesole D, Waage A, Laubach J, Munshi N, Gay F, Dimopoulos M, Rajkumar S, Mateos M, Cook G, Nahi H, Harrison S, Sezer O, Holstein S, Zweegman S, Usmani S, Boccadoro M, Hari P, Kaiser M, Costa L, Beksac M, Maiolino A, Leal da Costa F, Sidana S, Jurczyszyn A, Facon T, Durie B, Yong K, Martin T, Schjesvold F, Terpos E, Mikhael J, Ludwig H, Bahlis N, Zamagni E, Davies F, San Miguel J, Kumar S, Raje N, van de Donk N, Lonial S, Berdeja J, Hungria V, Baz R, Weisel K, Vangsted A, Fonseca R, Engelhardt M, Sonneveld P, Einsele H, João C, Anderson K, Hájek R, Lentzsch S, Kristinsson S, Cavo M, Moreau P. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. *Lancet Oncol* 2021; 22:e105–e118.

Ludwig H, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, Engelhardt M, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Abildgaard N, Bringhen S, Mateos M, Mohty M, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, Zweegman S, Facon T, Driessen C, Hájek R, Dimopoulos M, Gay F, Avet-Loiseau H, Terpos E, Zojer N, Sonneveld P. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. *Leukemia* 2020; 35:31–44.

Sonneveld P, von dem Borne P, Durian M, Hájek R, Boersma R, Wu K, Morelli A, Aquino S, Ludwig H, Bos G, Levin M, Benevolo G, Pascarella A, Troia R, Caravita di Toritto T, Zander T, Boccadoro M, Spencer A, Carvalho S, Palmas A, Cafro A, Mandigers C, Minnema M, van Marwijk Kooy M, Mellqvist U, Gimsing P, Waage A, Specchia G, Driessen C, Broijl A, Andersen N, Patriarca F, Palumbo G, Zamagni E, van der Velden V, Oliva S, Zweegman S, van der Holt B, Dozza L, Dimopoulos M, Petrucci M, Pantani L, Beksac M, Gay F, Montefusco V, Galli M, Liberati A, Zambello R, Vincelli I, Offidani M, Ballanti S, Croockewit A, Grasso M, Ypma P, Pour L, Belotti A, Hansson M, Gamberi B, Maisnar V, Cavo M. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. *Lancet Haematol* 2020; 7:e456–e468.

Caers J, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner H, Terpos E, Dimopoulos M, Driessen C, Larocca A, Garderet L, Kortüm K, O'Dwyer M, van de Donk N, Binder M, Dold S, Gay F, Corre J, Beguin Y, Ludwig H, Engelhardt M. An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when. *Haematologica* 2018

Ludwig H, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk N, Waage A, Beksac M, Mellqvist U, Engelhardt M, Caers J, Driessen C, Bladé J, Mateos M, Garderet L, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hájek R, Mohty M, Cavo M, Dimopoulos M, San-Miguel J, Terpos E, Zweegman S, Sonneveld P. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. *Leukemia* 2018

Yong K, Schoen P, Raab M, Mateos M, Karlin L, Safaei R, Gonzalez-McQuire S, Flinois A, Fink L, Driessen C, Delforge M, Cavo M. Multiple myeloma: patient outcomes in real-world practice. *Br J Haematol* 2016; 175:252-264.

Raab M, Schoen P, Mateos M, Karlin L, Safaei R, Gonzalez-McQuire S, Flinois A, Fink L, Driessen C, Delforge M, Cavo M, Yong K. Multiple myeloma: practice patterns across Europe. *Br J Haematol* 2016; 175:66-76.

Moreau P, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Zweegman S, Einsele H, van de Donk N, Miguel J, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Mateos M. Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. *Drugs* 2016; 76:989-990.

Moreau P, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Zweegman S, Einsele H, van de Donk N, San Miguel J, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Mateos M. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. *Drugs* 2016; 76:853-67.

Engelhardt M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos M, Einsele H, Sonneveld P, Palumbo A, Beksac M, Ludwig H, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen H, Hájek R, Driessen C, European Myeloma Network. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. *Haematologica* 2014; 99:232-42.

Engelhardt M, Straka C, Johnsen H, Waage A, Boegsted M, Lokhorst H, Hájek R, Morgan G, Boccadoro M, Ludwig H, Cavo M, Polliack A, Sonneveld P, Einsele H, Kropff M, Sezer O, Udi J, Kleber M, Spencer A, Rocci A, Knop S, Bruno B, Brighen S, Pérez-Simón J, Zweegman S, Driessen C, Patriarca F, Gramatzki M, Terpos E, Palumbo A. European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. *Leuk Lymphoma* 2010; 51:2006-11.

Ludwig H, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, Shpilberg O, Sondergeld P, Sonneveld P, Hess U, Harousseau J, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Zweegman S. Current multiple myeloma treatment strategies with novel agents: a European perspective. *Oncologist* 2010; 15:6-25.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)